US Product Portfolio

Medexus Pharma Products

Rasuvo®

Rasuvo is a once-weekly, subcutaneous, single-dose auto-injector of methotrexate indicated for the treatment of rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis (JIA).

Learn About Rasuvo

IXINITY®

IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B.  

Learn About IXINITY

Gleolan™

Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III and IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

Learn about Gleolan

Triamcinolone Hexacetonide

Medexus Pharma is coordinating with the U.S. Food and Drug Administration (FDA) to import Hexatrione 2% (triamcinolone hexacetonide), injectable suspension (intraarticular),20 mg/mL, for use in the United States.

Click here for the Dear Healthcare Provider letter with ordering information.
Click here for the FDA website link for more information.

These products may not be right for you. Always read and follow the label.

The contents of this site are for informational purposes only and are not intended, nor should they be used, as a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician, pharmacist or other qualified health care provider with any questions you may have regarding a medical condition and/or the use of these products. Also read the product monograph and/or the consumer information provided with the product.

About Medexus

About Medexus

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a highly scalable North American business model based on our fully integrated infrastructure (commercial operations, supply chain, regulatory, medical affairs and salesforce) already in place and a portfolio of specialty products that will underpin our growth for the next decade.

About Us

Corporate Responsibility

Medexus Pharma, Inc. is committed to creating a culture that encourages responsible corporate action at every level of our organization. We strive for the highest standards of business conduct and ethics.

Our Code of Conduct and Business Ethics illustrates the guiding ethical principles that support our commitment to compliance. Every day, we are faced with decisions and actions that give us the opportunity to embody the principles of our Code of Conduct. We are committed to maintaining an effective Compliance Program in accordance with federal and state government laws, regulations, and guidelines. We continually develop and implement policies, programs, and training activities to shape behaviors and help us achieve our compliance goals.

As part of the Medexus Pharma, Inc. continuing commitment to corporate compliance, Medexus Pharma, Inc. declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Policy as mandated by this California law. To the best of our knowledge, as of October 16, 2013, Medexus Pharma, Inc. is in substantial compliance with its Comprehensive Compliance Policy and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.

For a copy of our Comprehensive Compliance Policy, you may request a copy via our contact us form or by calling 1-855-336-3322.

Authorized Distributors of Record

This is a list of Authorized Distributors of Record (“ADRs”) with whom Medexus Pharma has an ongoing relationship to distribute Medexus Pharma products in the United States.

Click here for copy of ADR

Adverse Events

For adverse events, medical inquiries, and product related concerns, please call 1-855-336-3322.

Medical Affairs Support Initiatives

Medexus is committed to supporting the medical community through a variety of initiatives that enhance patient care in areas of unmet medical need.

For information regarding Investigator Initiated Trials (IITs), Independent Medical Education grants (IME) and Sponsorships, and how to request support, please click here.

Click here

US Headquarters

Medexus Pharma 
29 N Wacker 
Suite 704 
Chicago, IL 60606 
1-855-336-3322